207 related articles for article (PubMed ID: 16830272)
21. Immunohistochemical detection of EGFR, p185(erbB-2), Bcl-2 and p53 in breast carcinomas in pre-menopausal and post-menopausal women.
Talley L; Chhieng DC; Bell WC; Grizzle WE; Frost AR
Biotech Histochem; 2008 Feb; 83(1):5-14. PubMed ID: 18568671
[TBL] [Abstract][Full Text] [Related]
22. p53 and bcl-2 protein expression in rectosigmoid adenomas.
Papatheodoridis GV; Kapranos N; Tzouvala M; Triantafyllou K; Elemenoglou I; Karamanolis DG
Am J Gastroenterol; 1998 Jul; 93(7):1136-40. PubMed ID: 9672345
[TBL] [Abstract][Full Text] [Related]
23. The significance of allelic deletions and aneuploidy in colorectal carcinoma. Results of a 5-year follow-up study.
Cohn KH; Ornstein DL; Wang F; LaPaix FD; Phipps K; Edelsberg C; Zuna R; Mott LA; Dunn JL
Cancer; 1997 Jan; 79(2):233-44. PubMed ID: 9010096
[TBL] [Abstract][Full Text] [Related]
24. Expression of nm23-H1 gene product in sarcomatous cancer cells of renal cell carcinoma: correlation with tumor stage and expression of matrix metalloproteinase-2, matrix metalloproteinase-9, sialyl Lewis X, and c-erbB-2.
Ohba K; Miyata Y; Koga S; Kanda S; Kanetake H
Urology; 2005 May; 65(5):1029-34. PubMed ID: 15882758
[TBL] [Abstract][Full Text] [Related]
25. Correlates of urokinase-type plasminogen activator in colorectal cancer: positive relationship with nm23 and c-erbB-2 protein expression.
Berney CR; Yang J; Fisher RJ; Russell PJ; Crowe PJ
Oncol Res; 1998; 10(1):47-54. PubMed ID: 9613457
[TBL] [Abstract][Full Text] [Related]
26. Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival.
Casneuf VF; Fonteyne P; Van Damme N; Demetter P; Pauwels P; de Hemptinne B; De Vos M; Van de Wiele C; Peeters M
Cancer Invest; 2008 Oct; 26(8):852-9. PubMed ID: 18853313
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.
de Krijger RR; van der Harst E; van der Ham F; Stijnen T; Dinjens WN; Koper JW; Bruining HA; Lamberts SW; Bosman FT
J Pathol; 1999 May; 188(1):51-5. PubMed ID: 10398140
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
[TBL] [Abstract][Full Text] [Related]
29. Differential expression of Bcl-2, Bcl-XL and p53 in colorectal cancer.
Han HS; Park YM; Hwang TS
J Gastroenterol Hepatol; 2006 Jul; 21(7):1108-14. PubMed ID: 16824061
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.
Martínez-Arribas F; Alvarez T; Del Val G; Martín-Garabato E; Núñez-Villar MJ; Lucas R; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2007; 27(1A):219-22. PubMed ID: 17352236
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of bcl-2 in Dukes' stage B and C colorectal carcinoma patients: correlation with p53 and ki-67 in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2005; 56(4):179-85. PubMed ID: 16477877
[TBL] [Abstract][Full Text] [Related]
32. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
[TBL] [Abstract][Full Text] [Related]
33. Nm23-H1 expression does not predict clinical survival in colorectal cancer patients.
Dusonchet L; Corsale S; Migliavacca M; Calò V; Bazan V; Amato A; Cammareri P; Totaro MS; Agnese V; Cascio S; La Rocca G; Sisto PS; Dardanoni G; Valerio MR; Grassi N; Latteri S; Cajozzo M; Buscemi M; Castorina S; Morello V; Tomasino RM; Gebbia N; Russo A
Oncol Rep; 2003; 10(5):1257-63. PubMed ID: 12883690
[TBL] [Abstract][Full Text] [Related]
34. Molecular markers in gastric cancer: can p53 and bcl-2 protein expressions be used as prognostic factors?
Zafirellis K; Karameris A; Milingos N; Androulakis G
Anticancer Res; 2005; 25(5):3629-36. PubMed ID: 16101192
[TBL] [Abstract][Full Text] [Related]
35. [Prognosis value of p53, C-erB-2 and Ki67 proteins in ovarian carcinoma].
Frutuoso C; Silva MR; Amaral N; Martins I; De Oliveira C; De Oliveira HM
Acta Med Port; 2001; 14(3):277-83. PubMed ID: 11552325
[TBL] [Abstract][Full Text] [Related]
36. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
38. Analysis of both NM23-h1 and NM23-H2 expression identifies "at-risk" patients with colorectal cancer.
Brenner AS; Thebo JS; Senagore AJ; Duepree HJ; Gramlich T; Ormsby A; Lavery IC; Fazio VW
Am Surg; 2003 Mar; 69(3):203-8; discussion 208. PubMed ID: 12678475
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer.
Krause FS; Feil G; Bichler KH
Anticancer Res; 2000; 20(6D):5023-8. PubMed ID: 11326661
[TBL] [Abstract][Full Text] [Related]
40. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.
Rhee J; Han SW; Oh DY; Kim JH; Im SA; Han W; Park IA; Noh DY; Bang YJ; Kim TY
BMC Cancer; 2008 Oct; 8():307. PubMed ID: 18947390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
